Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome
| Autor: | D. Defilippis, Giovanni Barbara, Marc Pigrau, Maria Raffaella Barbaro, Teresa Iuvone, Beatriz Lobo, Cesare Cremon, Javier Santos, Fernando Azpiroz, Rosanna Cogliandro, Vincenzo Stanghellini, V. Di Marzo, Stefania Petrosino, María Vicario, C. Alonso Cotoner, Michel Neunlist, S. Bruley des Varannes, Lara Bellacosa |
|---|---|
| Přispěvatelé: | Cremon, C., Stanghellini, V., Barbaro, M.R., Cogliandro, R.F., Bellacosa, L., Santos, J., Vicario, M., Pigrau, M., Alonso Cotoner, C., Lobo, B., Azpiroz, F., Bruley des Varannes, S., Neunlist, M., Defilippis, D., Iuvone, T., Petrosino, S., Di Marzo, V., Barbara, G |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine Abdominal pain Analgesic Cell Count Palmitic Acids Pharmacology Placebo Young Adult 03 medical and health sciences chemistry.chemical_compound Oleoylethanolamide 0302 clinical medicine Double-Blind Method Glucosides Stilbenes Humans Medicine Pharmacology (medical) Mast Cells palmitoylethanolamide Irritable bowel syndrome irritable bowel syndrome Analgesics Palmitoylethanolamide Hepatology business.industry digestive oral and skin physiology Gastroenterology endocannabinoid Middle Aged Mast cell medicine.disease Amides Pathophysiology Abdominal Pain 030104 developmental biology medicine.anatomical_structure chemistry Ethanolamines Dietary Supplements Female 030211 gastroenterology & hepatology medicine.symptom business |
| Zdroj: | Alimentary pharmacology & therapeutics 45 (2017): 909–922. doi:10.1111/apt.13958 info:cnr-pdr/source/autori:Cremon, C.; Stanghellini, V.; Barbaro, M. R.; Cogliandro, R. F.; Bellacosa, L.; Santos, J.; Vicario, M.; Pigrau, M.; Alonso Cotoner, C.; Lobo, B.; Azpiroz, F.; des Varannes, S. Bruley; Neunlist, M.; DeFilippis, D.; Iuvone, T.; Petrosino, S.; Di Marzo, V.; Barbara, G./titolo:Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome/doi:10.1111%2Fapt.13958/rivista:Alimentary pharmacology & therapeutics/anno:2017/pagina_da:909/pagina_a:922/intervallo_pagine:909–922/volume:45 |
| DOI: | 10.1111/apt.13958 |
| Popis: | Background: Intestinal immune activation is involved in irritable bowel syndrome (IBS) pathophysiology. While most dietary approaches in IBS involve food avoidance, there are fewer indications on food supplementation. Palmithoylethanolamide, structurally related to the endocannabinoid anandamide, and polydatin are dietary compounds which act synergistically to reduce mast cell activation. Aim: To assess the effect on mast cell count and the efficacy of palmithoylethanolamide/polydatin in patients with IBS. Methods: We conducted a pilot, 12-week, randomised, double-blind, placebo-controlled, multicentre study assessing the effect of palmithoylethanolamide/polydatin 200mg/20mg or placebo b.d. on low-grade immune activation, endocannabinoid system and symptoms in IBS patients. Biopsy samples, obtained at screening visit and at the end of the study, were analysed by immunohistochemistry, enzyme-linked immunoassay, liquid chromatography and Western blot. Results: A total of 54 patients with IBS and 12 healthy controls were enrolled from five European centres. Compared with controls, IBS patients showed higher mucosal mast cell counts (3.2±1.3 vs. 5.3±2.7%, P=0.013), reduced fatty acid amide oleoylethanolamide (12.7±9.8 vs. 45.8±55.6 pmol/mg, P=0.002) and increased expression of cannabinoid receptor 2 (0.7±0.1 vs. 1.0±0.8, P=0.012). The treatment did not significantly modify IBS biological profile, including mast cell count. Compared with placebo, palmithoylethanolamide/polydatin markedly improved abdominal pain severity (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |